Ampel
Charlottesville, US · Virginia LLC
AMPEL BioSolutions develops RNA-based precision medicine products using its AMPEL Genomic Platform (AGP), which combines RNA analytics and predictive AI to evaluate disease status, identify cellular functions and pathways, and predict disease flares and drug targets from blood and biopsy tests. Its clinical products, such as LuGENE, DermaGENE, and WellGENE, support genomic diagnostics for patient disease management.
Founders & leadership
PL
Peter LipskyinCo-founderPeter Lipsky is a rheumatologist and immunologist who co-founded AMPEL BioSolutions, where he directs clinical operations for the company's RNA-based precision medicine platform and genomic diagnostics products.
AG
Amrie GrammerinCo-founder
Reported raises · per SEC filings
Form D private placements$4.8M disclosed across 5 rounds · 2019–2023
▶$1.8MraisedJul 2023 · 5 investors · BiotechnologyRule 506(b)
▶$1.8MraisedJul 2023 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter LipskyExecutive Officer
- Amrie GrammerExecutive Officer
- Offering amount
- $5M
- Amount sold
- $1.8M
- Minimum investment
- $100K
- First sale
- Apr 2023
- Incorporated
- Limited Liability Company, Virginia
- Federal exemptions
- 06b
▶$1.1MraisedDec 2022 · 3 investors · BiotechnologyRule 506(b)
▶$1.1MraisedDec 2022 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter LipskyExecutive Officer
- Amrie GrammerExecutive Officer
- Offering amount
- $5M
- Amount sold
- $1.1M
- Minimum investment
- $100K
- First sale
- Nov 2022
- Incorporated
- Limited Liability Company, Virginia
- Federal exemptions
- 06b
▶$350KraisedJun 2021 · 2 investors · BiotechnologyRule 506(b)
▶$350KraisedJun 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter LipskyExecutive Officer
- Amrie GrammerExecutive Officer
- Offering amount
- $5M
- Amount sold
- $350K
- Minimum investment
- $100K
- First sale
- May 2021
- Incorporated
- Limited Liability Company, Virginia
- Federal exemptions
- 06b
▶$500KraisedFeb 2021 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedFeb 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter LipskyExecutive Officer
- Amrie GrammerExecutive Officer
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $150K
- First sale
- Nov 2019
- Incorporated
- Limited Liability Company, Virginia
- Federal exemptions
- 06b
▶$1MraisedJan 2021 · 5 investors · BiotechnologyRule 506(b)
▶$1MraisedJan 2021 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter LipskyExecutive Officer
- Amrie GrammerExecutive Officer
- Offering amount
- $4M
- Amount sold
- $1M
- Minimum investment
- $100K
- First sale
- Dec 2020
- Incorporated
- Limited Liability Company, Virginia
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Ampel for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Ampel do?
- AMPEL BioSolutions develops RNA-based precision medicine products using its AMPEL Genomic Platform (AGP), which combines RNA analytics and predictive AI to evaluate disease status, identify cellular functions and pathways, and predict disease flares and drug targets from blood and biopsy tests. Its clinical products, such as LuGENE, DermaGENE, and WellGENE, support genomic diagnostics for patient disease management.
- Who founded Ampel?
- Ampel was founded by Peter Lipsky, Amrie Grammer.
- How much funding has Ampel raised?
- Ampel has disclosed $4.8M raised across 5 rounds.
- Where is Ampel headquartered?
- Ampel is headquartered in Charlottesville, US.